|
|
|
||
(State or other jurisdiction of
incorporation) |
(Commission File Number)
|
(I.R.S. Employer
Identification No.) |
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
|
|
The
|
August 30, 2023
|
/s/ Greg Weaver
|
Greg Weaver
Executive Vice President and Chief Financial Officer |
Document And Entity Information |
Aug. 30, 2023 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | Atossa Therapeutics, Inc. |
Document, Type | 8-K |
Document, Period End Date | Aug. 30, 2023 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-35610 |
Entity, Tax Identification Number | 26-4753208 |
Entity, Address, Address Line One | 107 Spring Street |
Entity, Address, City or Town | Seattle |
Entity, Address, State or Province | WA |
Entity, Address, Postal Zip Code | 98104 |
City Area Code | 206 |
Local Phone Number | 588-0256 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity, Emerging Growth Company | false |
Title of 12(b) Security | Common Stock, $0.18 par value |
Trading Symbol | ATOS |
Security Exchange Name | NASDAQ |
Amendment Flag | false |
Entity, Central Index Key | 0001488039 |
&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " JI1Y7 M99!YDAD! #/ P $P @ &B$@ 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 "0 ) #X" #L$P ! end